Introduction
Angiogenesis is triggered by a change in balance between different pro-and anti-angiogenic activities that regulate the behavior of capillary endothelial cells (Hanahan and Folkman, 1996) . In this regard, a pre-eminent role has been established for the vascular endothelial growth factor (VEGF)-related family of angiogenic and lymphangiogenic growth factors, which currently includes VEGF-A, -B, -C, -D, -E, and placenta growth factor (PlGF). VEGF-A is believed to play an indispensable role in angiogenesis. Indeed, targeting of the VEGF-A gene in mice resulted in early embryonic lethality due to severe structural and functional abnormalities in the developing vasculature, even when only a single VEGF-A allele was inactivated (Carmeliet et al., 1996; Ferrara et al., 1996) . Embryonic lethality is also induced by targeted disruption of either of the two main VEGF receptors expressed by endothelial cells, namely VEGFR-2 (Flk-1/KDR) and VEGFR-1 (Flt-1), the former regarded as the main transducer of positive pro-angiogenic signals (Carmeliet, 2000) . The profound in¯uence of the VEGF/VEGF receptor axis on vascular development and angiogenesis is likely linked to its role as a stimulator of endothelial cell survival, mitogenesis, migration, differentiation and self-assembly, as well as vascular permeability and mobilization of endothelial progenitor cells (EPCs) from the bone marrow into the peripheral circulation (Ferrara and Gerber, 2001 ).
There are numerous reasons to suggest that VEGF also plays an important role in`pathological' forms of angiogenesis, including tumor neovascularization (Ferrara and Gerber, 2001 ). For instance, VEGF expression is elevated in the majority of human cancers, and in many transformed cell lines in culture (Dvorak et al., 1995) . Furthermore, transforming genetic lesions such as activated oncogenes (ras, neu/HER-2 and at least 20 others) (Rak and Kerbel, 2003) and inactivated tumor suppressor genes (e.g. p53, VHL, PTEN, INK4a/p16) have a direct stimulating impact on VEGF expression in cancer cells (Bouck et al., 1996) . A causative role for VEGF in tumor angiogenesis has been implicated by numerous studies (Claffey et al., 1996; Ferrara and Gerber, 2001) . In this regard, particularly striking are the results involving wildtype (Ferrara et al., 1996) or oncogenically transformed embryonic stem (ES) cells (Shi and Ferrara, 1999) , embryonic ®broblasts (Grunstein et al., 1999) or endocrine pancreatic cells (Inoue et al., 2002) , in all of which total inactivation of the VEGF gene was found to result in severe suppression of tumorigenic and angiogenic phenotypes. These studies suggest implicitly that not only is VEGF essential and indispensable for tumor growth and neovascularization, but also that tumor cells themselves constitute the major source of VEGF.
There are, however, experimental ®ndings that seem to be at variance with the notion that VEGF is a nonredundant tumor angiogenesis factor that is predominantly produced by cancer cells. For example, appreciable VEGF expression has been detected in tumor-associated ®bro-blasts (Hlatky et al., 1994; Fukumura et al., 1998; Kishimoto et al., 2000) and in¯ammatory cells (Coussens et al., 1999) . This suggests that the host stromal Contrasting effects of VEGF gene disruption in embryonic stem cell-derived versus oncogene-induced tumors The EMBO Journal Vol. 22 No. 16 pp. 4091±4102, 2003 ã European Molecular Biology Organization compartment may constitute a major source of VEGF in tumors (Fukumura et al., 1998) . It has also been observed that reduction of VEGF expression in cancer cells may be functionally insigni®cant in certain advanced experimental tumors (Yoshiji et al., 1997) , and that tumor progression is associated with expression of an increasing number of different pro-angiogenic growth factors, in addition to VEGF (Relf et al., 1997) . Moreover, while the anti-tumor effects of neutralizing antibodies and pharmacological antagonists of VEGF or its receptors have been promising in many cases (Kim et al., 1992; Ferrara and Gerber, 2001) , in other instances the responses have been variable, transient and sometimes rather modest in magnitude, especially in advanced tumors (Garber, 2002) . Indeed, a direct analysis has been lacking as to how critical the role of tumor cell-derived versus stromal VEGF is in various tumor angiogenesis settings.
The purpose of our study was to address this question by investigating two fundamentally different forms of tumorigenesis (and associated angiogenesis) occurring in either the presence or absence of the functional VEGF gene and protein expression in cancer cells. Our data indicate that teratomas derived from totipotent (genetically intact) ES cells were absolutely VEGF dependent. In contrast, adult mouse dermal ®broblasts expressing mutant ras or neu oncogenes remained tumorigenic even if rendered VEGF-null. Such tumors recruited VEGFexpressing host cells and down-regulated at least two potent angiogenesis inhibitors, such as pigment epithelium derived factor (PEDF) and thrombospondin 1 (TSP-1). Thus, VEGF production by cancer cells may be nonessential in the context of oncogene-driven tumorigenesis.
Results

Tumorigenic properties of VEGF-de®cient ES cells
We decided to test the limits of VEGF involvement in tumor angiogenesis by comparing the impact of VEGF deletion on the tumor forming capacity of ES cell-derived teratomas or their related, but adult, cell descendants transformed with mutant oncogenes.
First, we employed the R1 strain of ES cells (Nagy et al., 1993) . Both wild-type R1 cells (wtR1) and their VEGFde®cient counterparts (clones 44.7 and 36.8) were injected subcutaneously (s.c.) into SCID mice. As expected, inoculation of wtR1 cells resulted in the rapid growth of aggressive and highly vascularized teratomas (Ferrara et al., 1996) (Figure 1 ). Such tumors display a complex morphology and contain a rich network of CD31-positive host blood vessels (Yu et al., 2001) . In marked contrast, R1 cells in which the VEGF gene was disrupted were unable to form tumors for at least 50 days after inoculation of as many as 7 3 10 6 cells ( Figure 1A ). As growth in vitro of both types of ES cells is not in¯uenced by their VEGF status (data not shown), we attributed these in vivo properties of teratomas to VEGF-dependent angiogenesis. Indeed, treatment of mice harboring wild-type R1 tumors with a neutralizing antibody (DC101) directed against VEGFR-2/¯k-1 resulted in nearly complete inhibition of tumor growth ( Figure 1B) . Collectively, these observations are in keeping with the notion that the endogenous production of VEGF and its interaction with endothelial VEGFR-2 are essential events during formation and vascularization of murine R1 teratoma.
Generation of VEGF-de®cient oncogenetransformed ®brosarcoma cell lines
In contrast to the epigenetic nature of ES cell-derived teratomas, the majority of human tumors harbor various transforming genetic alterations. In order to assess the role of VEGF in the latter type, i.e oncogene-driven tumor angiogenesis, we generated a series of oncogene-transformed VEGF-pro®cient (VEGF +/+ ) or VEGF-de®cient (VEGF ±/± ) ®brosarcoma cell lines. As summarized in Figure 2A , 4-to 5-month-old chimeric (VEGF ±/± ,VEGF +/+ ) mice were used as donors of skin explants. Primary cultures of dermal ®broblasts were subsequently established and infected with a retrovirus expressing both ras and myc oncogenes (Soloway et al., 1996) . Alternatively, VEGF ±/± ®broblasts were spontaneously immortalized and the resulting cell line (MDF528) was transfected with expression vectors encoding either an activated H-ras or neu oncogene ( Figure 2A ). All cell lines harboring mutant oncogenes (but not the MDF528 immortalized parental cells or their 528Hp hygromycinresistant vector transfectants) exhibited the usual features of morphological trasformation ( Figure 2B ), formed foci in monolayer culture and grew as colonies in semi-solid media (data not shown). VEGF status in all transformed and non-transformed cell lines was veri®ed by testing for G418 resistance (conferred by the VEGF targeting vector), Southern analysis and direct determination of VEGF mRNA and protein expression ( Figure 3A±D ).
Tumorigenic properties of VEGF ±/± cell lines expressing activated oncogenes In marked contrast to ES cell-induced teratomas, 100% tumor take occurred in the case of all oncogene-driven ®brosarcomas regardless of their VEGF status, and this was followed by aggressive growth ( Figure 4A±C ; Table I ) of highly vascular tumors (see Figure 7A±C ). However, the overall growth kinetics of VEGF ±/± ras-or neudependent ®brosarcomas was somewhat slower than that of their VEGF +/+ 3T3ras counterparts ( Figure 4A ) or 528rasmV1-7 cells engineered to re-express mouse VEGF 164 ( Figure 4B ). The relative aggressiveness in vivo of various ®brosarcomas also correlated with their apparent degree of cellular transformation. Thus, 528neu7 cells, with lower expression of activated NEU (Figures 2B and 4D) , were considerably less aggressive in vivo ( Figures 4C  and 6C ) than more transformed 528neu3 and 528neu2 cell lines. Collectively, these results suggest that in the case of oncogene-driven tumors, malignant growth capacity in vivo is not dependent on VEGF production by cancer cells (unlike in teratomas). 
Oncogenes, tumor angiogenesis and VEGF
We reasoned that stromal cells could be a source of VEGF in VEGF-de®cient tumors, and if so, the administration of VEGFR-2 antagonists could still suppress tumor growth. Therefore, mice harboring 528neu3 tumors were treated with the DC101 antibody (against mouse VEGFR-2), and tumor growth inhibition of up to 50% ( Figure 5A ), as well as~2-fold reduction in microvascular density, were indeed observed ( Figure 5C ). However, responsiveness to such treatment (DC101, 800 mg twice a week) was negligible in the case of two other ®brosarcomas (i.e. 528neu2 and 528ras1; Figure 5A and B, respectively). This suggests that activation of the VEGF/VEGFR-2 pathway by tumor stroma is not a sine qua non in ®brosarcoma.
Expression of VEGF by host stromal cells recruited by oncogene-driven tumors Regardless of their responsiveness to VEGFR-2 inhibition, ample stromal cell in®ltration was observed in all oncogene-driven ®brosarcomas tested. For instance, even in relatively DC101-unresponsive 528ras1 tumors, Southern analysis revealed both the wild-type (host) and the targeted VEGF alleles (the former being absent in cultured cells) (Figures 3A and 6A) . Moreover, Figure 6 shows that in contrast to various 528ras and 528neu VEGF-de®cient cultured cell lines, the material explanted from the corresponding tumors contained measurable quantities of VEGF mRNA ( Figure 6B ) and protein ( Figure 6D ). Although VEGF was detectable in the original tumor masses, cancer cell lines re-established from such tumors (528rasT1, 528rasT2) were still devoid of any VEGF expression, even when exposed to various serum concentrations or to cobalt chloride ( Figure 3C ). Interesting but presently unexplained differences in the expression of stromal VEGF and microvascular vascular densities (MVD) were noted between ®brosarcomas with different levels of oncogenic transformation (e.g. 528neu7 versus 528neu 3) ( Figures 4D, 6D , and 7B and C). Overall, these results can be interpreted as an (indirect) indication that, while (cultured) tumor cells of the 528 series were completely VEGF-negative, VEGF-positive stromal cells were, in fact, relatively abundant in the corresponding in vivo tumors.
To gain a more direct insight into the cellular sources of the stromal-derived VEGF, we injected 528ras or 528neu cells into syngeneic or SCID mice harboring the yellow¯uorescent protein (YFP) transgene. Confocal images (Figures 7H±J) of the resulting tumors revealed a rich network of YFP-positive host cells (tumor cells being non-¯uorescent) detectable at the boundary between the YFP-negative tumor cell masses and the overlaying YFP-positive skin ( Figure 7H ). YFP-positive cells were also present within the tumor interior and decorated vascular channels and their surroundings (Figure 7I and J) . By immunostaining of the corresponding tumor sections we were able to positively identify numerous endothelial cells (CD31-positive) comprising tumor capillaries ( Figure 7A±C ). Those were not associated with pericytes, unlike vessels present in the surrounding connective tissues ( Figure 7D and E). In addition, CAE-positive single mast cells were detected in the tumor periphery ( Figure 7F ). Diffused speci®c staining for ®broblastic markers (vimentin) was detected In some cases a larger transcript was detectable as described previously (Ferrara et al., 1996) . (C) Absence of VEGF in conditioned medium of MDF528-derived cell lines (VEGF ELISA) treated with VEGF inducers (various FBS concentrations and/or CoCl 2 ). 528ras1T1 and 528ras1T2 are cell lines reestablished in culture from tumors that arose after s.c. injection of 528ras1 cells. (D) VEGF levels in ras/myc-transformed clones of primary dermal ®broblasts isolated from chimeric VEGF-positive/negative mice. Transformed clones with a targeted VEGF gene were negative for VEGF protein expression, whereas their G418 sensitive (nontargeted VEGF) counterparts from the same culture produced an abundance of VEGF, particularly in the presence of CoCl 2 . High serum levels caused a decrease in VEGF production by VEGF +/+ transformed cell lines.
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throughout ®brosarcomas. This staining was somewhat more intense within the connective tissue surrounding and in®ltrating the tumors than within the parenchyma ( Figure 7G ).
Direct evidence for VEGF production by stromal cells in®ltrating VEGF-negative tumors came from experiments with mice harbouring the LacZ-tagged VEGF allele (Miquerol et al., 1999) . Because the VEGF-LacZ cassette is under control of the endogenous, unmodi®ed VEGF promoter, individual stromal cells expressing VEGF can be detected by LacZ staining in a more reliable manner than in other VEGF reporter systems based on the exogenous VEGF promoter (Kishimoto et al., 2000) . As shown in Figure 7K and L, numerous LacZ-positive ®broblast-like stromal cells were detected throughout the tumors and in para-vascular areas. This experiment demonstrates directly that at least some elements of the tumor stroma actively produce VEGF in situ, and that detection of this growth factor in whole tumor lysates was not a result of`contamination' with blood cells and/or platelets.
Pleiotropic effects of ras and neu oncogenes on the angiogenic phenotype Despite the presence of VEGF-positive stroma, growth of VEGF ±/± ®brosarcomas was, for the most part, only partially inhibited by the DC101 antibody, even when administered at doses that obliterated growth of ESderived teratomas (compare Figure 5A and B with Figure 1 ). It follows that in oncogene-driven tumors, angiogenic switching' continues to occur despite the absence of VEGF production by tumor cells and inactivation of the endothelial VEGFR-2. This implies additional/ alternative (VEGF-unrelated) pro-angiogenic mechanisms. In order to assess this aspect, we performed a targeted gene expression screen involving 23 known angiogenesis-related transcripts (Figure 8 ; see Materials and methods). GEArray is a version of a`reverse northern' analysis where speci®c probes are immobilized on a membrane, which is then exposed to a pool of reversetranscribed (radiolabeled) cellular cDNA. Such comparison between parental MDF528 cells and either ras-or neu-transformed ®brosarcoma counterparts indicated the existence of several oncogene-induced changes. Thus, acidic (aFGF), basic (bFGF) ®bro-blast growth factors and VEGF-B were all up-regulated in both ras-and neu-transformed cells as compared to their parental control MDF528 ®broblasts. A moderate increase in expression of transforming growth factor a (TGF-a) and angiopoietin 2 (Ang2) was also observed (mainly in 528ras1 cells), along with several less consistent changes (e.g. affecting PF-4, PAI-1, uPA). However, when tumor-derived RNA was analyzed instead of RNA isolated from the cultured cell lines, many of these changes were no longer detectable, with the exception of a modest increase in expression of bFGF in 528ras1 tumors ( Figure 8A ). Interestingly, both transformed cell lines (528neu3, 528ras1) and 528ras1 tumors reproducibly displayed transcript downregulation for at least two different angiogenesis inhibitors: PEDF and TSP-1. In fact, the magnitude of TSP-1 downregulation by ras and neu oncogenes appears to be underestimated by GEArray analysis, as indicated by near complete suppression of TSP-1 expression in northern blots performed with several tumor cell lines, including 528neu3 ( Figure 8B ), 528ras5 and 528ras1 ( Figure 8C ), relative to control cell lines (MDF528 and 528Hp/ MDF528hygro). This result was con®rmed at the protein level in both cultured cell lines and tumors (data not shown).
Because of the magnitude, consistency and apparent generality of TSP-1 down-regulation observed in various oncogene-harboring cell types (Zabrenetzky et al., 1994; Rak et al., 2000; Watnick et al., 2003) , we decided to examine the functional signi®cance of this change in the context of VEGF-de®cient 528ras1 cells. In order to reconstitute the anti-angiogenic TSP-1 activity in the environment of 528ras1 tumors, we decided to systemically administer TSP-1 peptides derived from the type I (properdin-like) repeats believed to participate in crucial interactions between TSP-1 and its endothelial cell CD36 receptor Reiher et al., 2002) . Figure 8D shows that systemic administration of such a TSP-1 peptide (ABT-526) resulted in marked and speci®c (albeit incomplete) growth inhibition of 528ras1 ®brosar-coma in vivo, even at relatively low doses (3 mg/kg). A much higher dose (30 mg/kg) of ABT-526 induced a somewhat greater (70%) but still incomplete anti-tumor effect. This effect was coupled with a decrease in vascular hot spot' MVD ( Figure 8E ). Interestingly, while we did not observe aSMA(+) vessels in untreated ®brosarcoma tumors ( Figure 7D ), such vessels (albeit only a fraction of all) were detectable in tumors exposed to the TSP-1 peptide ( Figure 8F ). Overall, these observations support the notion that suppression of TSP-1 activity represents an important aspect of the ras-dependent angiogenic phenotype. 
Discussion
While our results overall are consistent with the importance of VEGF in tumor angiogenesis, they challenge the perceived generic nature of this relationship. Indeed, we describe two pathways of tumor-induced angiogenesis, which differ fundamentally in their genesis (epigenetic versus genetic), their absolute dependence on tumor cellderived VEGF, and on the apparent relative contribution of the VEGF/VEGFR-2 pathway as such (Figure 9 ). Thus, in the case of epigenetically driven (tumor) angiogenesis exempli®ed by ES cell-induced teratomas, both VEGF production and biological activity (particularly the aspect mediated by VEGFR-2) are clearly essential and indispensable for tumor (teratoma) formation. This is consistent with other reports, in which obliteration of VEGF production in tumorigenic cell lines of embryonal origin resulted in suppression of their malignant properties (Ferrara et al., 1996; Grunstein et al., 1999 Grunstein et al., , 2000 Shi and Ferrara, 1999; Tsuzuki et al., 2000) . Also, development of spontaneous endocrine insulinomas under the in¯uence of the early region of the SV40 large T oncogene (Rip-Tag mice) was recently shown to be inhibited in the context of conditional VEGF-deletion (VEGF¯/¯) (Inoue et al., 2002) . It is noteworthy that in this study, the transforming genetic lesion is present in mice throughout embryonic and post-embryonic periods, and malignant disease develops in relatively young animals (10± 16 weeks). Moreover, this process affects an organ (pancreatic beta islets), which unlike many non-endocrine tissues is a priori VEGF-positive (Dvorak et al., 1995) , and possibly VEGF-dependent for its normal function. These circumstances could conceivably separate the RipTag model of tumorigenesis from cancers occurring in non-endocrine and VEGF-negative adult tissues.
In sharp contrast to the indolent behavior of VEGF ±/± teratomas, their genetically related, VEGF ±/± oncogeneinduced ®brosarcomas exhibited a robust tumorigenic and angiogenic phenotype in vivo. Clearly, in this case, genetically altered (transformed) tumor cells were able to substitute for VEGF de®ciency by triggering alternative/additional angiogenic (and tumorigenic) pathways. It is noteworthy that all VEGF ±/± ®brosarcoma cells used in our study were derived from dermal connective tissue of mice that were at least 4±5 months of age, a circumstance that sharply separates these cells from their totipotent VEGF ±/± ES ancestors and other embryonic cell types often used for tumor studies.
Our in situ analyses revealed numerous, elongated (®broblastoid) VEGF expressing host stromal cells within Figure 4D ). Only tumors of equivalent size (700 mm 3 ) were compared in this assay.
Oncogenes, tumor angiogenesis and VEGF 528ras and 528neu tumors. However, the functional signi®cance of such stromal VEGF production in cancer is a subject of considerable controversy. Thus, the absolute abrogation of tumorigenesis by targeting the VEGF gene in various experimental tumor systems (e.g. in ES cellderived teratomas) implicitly suggests that VEGF-positive host stromal cells make a negligible contribution in these instances (Ferrara et al., 1996; Grunstein et al., 1999 Grunstein et al., , 2000 Shi and Ferrara, 1999; Tsuzuki et al., 2000; Inoue et al., 2002) . This is contrary to strong, albeit circumstantial, suggestions that stromal VEGF production plays a critical role in tumor angiogenesis (Hlatky et al., 1994; Fukumura et al., 1998) . Ironically, a rigorous inquiry in this regard would require exclusion of tumor cell-derived VEGF (i.e. analysis of tumors that are VEGF-de®cient). By using such VEGF ±/± oncogene-driven tumors we have demonstrated that the contribution of stromal VEGF to overall angiogenic competence in vivo is variable, modest and mostly non-essential. This is apparent from experiments in which two out of three VEGF ±/± ®brosarcomas tested were only slightly growth inhibited by obliteration of VEGFR-2 activity. Our results bear an intriguing resemblance to the outcome of the recent phase III clinical trial in which a speci®c monoclonal anti-VEGF antibody (bevacizumab/Avastin â ) unexpectedly failed to meet the ef®cacy endpoints when used (in combination with Xeloda â chemotherapy) to treat patients with advanced metastatic breast cancer (Garber, 2002) . Our experimental observations suggest that such a failure might be indicative of a decline in the importance of the VEGF/VEGFR-2 pathway that may follow genetic tumor progression.
Oncogenic transformation is often associated with a multitude of molecular alterations (Zuber et al., 2000) . In this regard, increasing contribution of pro-angiogenic growth factors other than VEGF has been detected in human tumors (Relf et al., 1997; Yoshiji et al., 1997) . Our GEArray pro®ling also suggests several potentially relevant alternative changes in gene expression including upregulation of angiogenesis stimulators (aFGF, bFGF, TGF-a, VEGF-B) or down-regulation of inhibitors (TSP-1, PEDF, PAI-1). In some instances these changes were associated with a particular oncogene (e.g. Ang1 down-regulation in ras-but not in neu-transformed cells). At least two different angiogenesis inhibitors, TSP-1 and PEDF, were altered both in vitro and in VEGF-de®cient tumors (528ras1) in vivo. Interestingly, the latter changes were detected despite the presence of stromal cell material in tumor preparations. This may suggest an even greater magnitude of change in cancer cells or altered expression of TSP-1 and PEDF in stromal cells in vivo (a`®eld effect') (Rak and Kerbel, 2003) .
TSP-1 is of particular interest as a potent and wellstudied angiogenesis inhibitor , and a known target of several transforming genes (Dameron et al., 1994; Zabrenetzky et al., 1994; Izumi et al., 2002) . A detailed pathway of this regulation by ras has recently been delineated (Watnick et al., 2003) . Our results with the anti-angiogenic TSP-1 peptide (ABT-526) suggest that the loss of TSP-1 expression is a signi®cant event during tumor progression driven by oncogenes, but also emphasize the multi-factorial nature of such proangiogenic in¯uences. Thus, even in the presence of potent TSP-1 peptides combined with VEGF de®ciency (of tumor cells), growth of oncogene-driven ®brosarcomas was not obliterated completely. This may signify a redundancy of angiogenic pathways (e.g. impact of PEDF; and/or the possible oncogene-dependent changes in vascular dependence of cancer cells, something that we have recently suggested (Rak et al., 2002) . Of note, TSP-1 peptides provoked not only reduction in MVD but also a trend towards the appearance of aSMA(+)/pericytecovered blood vessels within the interiors of 528ras (F) Appearance of aSMA(+) blood vessels in 528ras tumors exposed to ABT-526. Fig. 9 . Bypassing VEGF-dependence during oncogene-induced tumor angiogenesis. Totipotent ES cells form tumors (teratomas) upon s.c. inoculation due to perturbations in their differentiation program, in the apparent absence of stable genetic alterations and in a manner entirely dependent on VEGF-driven tumor angiogenesis. In contrast, tumors cells harbouring mutant oncogenes may develop redundant angiogenic VEGF-independent pathways involving changes in endogenous expression of angiogenesis stimulators and inhibitors, and recruitment of a pro-angiogenic tumor stroma. Consequently, in some cases VEGF production by oncogene-expressing cancer cells could become dispensable for tumor growth and angiogenesis in vivo.
Oncogenes, tumor angiogenesis and VEGF tumors, which normally express very low levels of Ang-1 and no aSMA(+) vasculature. It remains to be seen whether TSP-1 has any direct impact on the Ang-1/tie-2 pathway. Apart from its anti-angiogenic effects, TSP-1 may also exhibit some direct inhibitory activity against cancer cells (Lawler, 2002) , something that we have detected with 528ras cells engineered to overexpress TSP-1 or exposed to high concentrations of ABT-526 peptide (not shown).
Here we describe considerable differences in the role of VEGF during formation of teratomas versus oncogeneinduced ®brosarcomas. Naturally occurring human tumors may be closer to one end or the other of this spectrum, depending on the cell/tumor type, and whether genetic or epigenetic in¯uences predominate in expression of their pro-angiogenic characteristics. Carcinomas could obviously also differ from ®brosarcomas. Nevertheless, our study suggests that the functional role of VEGF in cancer is not always indispensable, regardless of its apparent presence.
Materials and methods
Cell lines and culture conditions R1 ES cells and their VEGF ±/± variants were cultured as previously described (Nagy et al., 1993; Carmeliet et al., 1996) . ES cells were cultured on 0.5% gelatin (Sigma) in Dulbecco's modi®ed Eagle's medium (DMEM), with 20% fetal bovine serum (FBS; Hyclone), 2000 U of leukemia inhibitory factor (LIF), with or without mitomycin C (Sigma)-treated feeders. All other cell lines were maintained in DMEM, 5% FBS (Gibco-BRL) under standard conditions (37°C, 5% CO 2 ). Dr M.-Ch.Hung (M.D. Anderson Cancer Center, Houston, TX) generously provided B104.1.1 cells, while the packaging cell line expressing the ecotropic ras/myc retrovirus was a gift from Dr Paul Soloway (Roswell Park Memorial Institute, Buffalo, NY) (Soloway et al., 1996) .
Generation of VEGF-de®cient and VEGF-pro®cient ®broblastic cell lines Chimeric mice were generated by in vitro aggregation from VEGF ±/± R1 ES cells (129X1/Sv 3 129S1/SvJ) and eight-cell stage embryos of wildtype (VEGF +/+ ) mice (CD1), as described previously (Tanaka et al., 1997) . The resulting aggregates were implanted into surrogate mothers and embryos were allowed to develop to term. The degree of chimerism (usually <20%) was assessed by the presence of agouti (ES cell-derived, VEGF ±/± ) or albino (CD1, VEGF +/+ ) skin patches. Chimera were killed at 4±5 months and skin fragments were explanted, trypsinized overnight at 4°C, stripped of epidermis and digested with collagenase, hyaluronidase and elastase. Dermal ®broblasts were allowed to attach and expand in culture. Some primary cultures were transformed with the retrovirus expressing ras and myc oncogenes and foci subcloned into duplicates. These were grown with and without 400 mg/ml of G418 (Gibco-BRL) such that VEGF ±/± or VEGF +/+ cells could be identi®ed based on their G418 resistance. Independent sets of primary ®broblastic cultures were subjected to serial passage in the presence of G418 for 5 months, whereby a polyclonal, spontaneously immortalized, VEGF ±/± cell line (MDF528) was established (Figure 2 ). This cell line was subsequently transfected with expression vectors encoding either mutant (V12) H-ras or activated HER-2/neu oncogenes using a lipofectin protocol (Gibco-BRL) and pcDNA3.1Zeo or pcDNA3.1Hygro (both from Invitrogen) for an additional selectable marker. Multiple transfected MDF528-derived clones were isolated and their transformed phenotype assessed morphologically, by focus and soft agar colony formation assays. The expression of both H-Ras and HER-2/NEU proteins was veri®ed by western blotting with pan-RAS antibody (Oncogene Science), or immunoprecipitation with the anti-NEU antibody SC-284 (Santa Cruz Biotechnologies) followed by staining with phosphotyrosine-speci®c antibody 05-321 (Upstate Biotechnology). In cell lines expressing ras or neu (designated 528ras or 528neu, respectively; Figure 2 ) murine VEGF 164 or LacZ (control) was expressed by transfection (vector was kindly provided by Dr Kevin Claffey). The resulting cell lines (e.g. 528rasmV and 528rasLZ, respectively) expressed additional selectable markers due to co-transfection with pcDNA3.1Hygro or pcDNA3.1Zeo (Invitrogen). Finally the VEGF status of all cell lines was veri®ed by a combination of Southern (with exon 8 genomic sequence of VEGF), northern (exon 1±5 cDNA obtained from Dr Harold Dvorak), VEGF mRNA enzyme-linked immunosorbent assay (ELISA) (R&D Systems) and mouse VEGF protein ELISA (R&D Systems). The ®broblastic nature of cell lines was con®rmed by morphology, growth requirements and staining with anti-vimentin antibody (see below).
Determination of VEGF protein and RNA VEGF protein levels were determined in either conditioned medium or tumor homogenates using a mVEGF ELISA kit (R&D Systems) in the presence or absence of FBS (1%, 5%, 10%), and/or 100 mM cobalt chloride (CoCl 2 ), a hypoxia mimetic (Minchenko et al., 1994) . The medium was conditioned for 24 h, cleared by high-speed centrifugation and stored at ±70°C. The cell number/well was used for assay normalization. Tumor fragments (~0.5 g) were minced into small pieces and homogenized [in phosphate-buffered saline (PBS) on ice] with Virtishear blender (The Virtis Company, Inc.). Tumor homogenates were then cleared by centrifugation and supernatants stored at ±70°C. Total RNA was isolated from either cultured cells or tumor tissue using TRIzol reagent (Life Technologies). To quantify expression of the mVEGF transcript, 5±10 mg of total RNA was applied to the Quantikine â mRNA kit (R&D Systems) or 10±50 mg of such RNA was analyzed by northern blotting, as described previously (Rak et al., 2000) .
Tumor implantation analysis and in vivo treatments
All cell lines were tested for tumorigenic and angiogenic capacity in SCID mice 6±8 weeks of age (unless indicated otherwise). Brie¯y, 1±5 3 10 6 transformed or non-transformed (MDF528) ®broblastic cells were injected orthotopically (s.c.) in 0.2 ml PBS. In the case of R1 (ES) cells and their two independent VEGF ±/± clones (36.8 and 44.7) 5±7 3 10 6 cells/mouse were inoculated (s.c.). Tumor take and growth were followed by measurements with the vernier caliper, followed by tumor volume calculation as a function of time (Rak et al., 2000) . Most cell lines and treatment conditions were tested in groups of 5±10 mice (occasionally four mice) and repeated at least twice (sometimes up to ®ve times) with similar results. Neutralizing monoclonal antibody against mouse VEGFR-2 (DC101) was generated by ImClone Systems Inc. (New York, NY). This antibody was reconstituted in sterile PBS and injected intraperitoneally into tumor bearing mice twice a week, starting 1±4 days after tumor cell injection (unless otherwise indicated). An effective dose of DC101 (800 mg per injection) was previously established (Lyden et al., 2001) . The nonapeptide (Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-Proethylamide), which contains a fragment of the second type-I TSP-1 repeat (ABT-526 or DITSP), was generated by Abbott Laboratories. The peptide was dissolved in 5% dextrose and injected s.c. into tumor bearing SCID mice twice daily. Treatment was initiated 1 day after injection of 10 6 528ras1 cells s.c. All animal experiments were performed in accordance with guidelines of the Canadian Council of Animal Care (CCAC) and McMaster University's Animal Research Ethics Board (AREB).
Histological analysis and immunohistochemistry
Formalin-®xed, paraf®n-embedded specimens of 528neu or 528ras tumors were sectioned (5±7 mm) and processed for gross histological analysis (hematoxylin and eosin), and immunostaining for aSMA, desmin or chloroacetate esterase (CAE) histochemistry, as described elsewhere (Coussens et al., 1999) . Anti-aSMA antibody A-2547 (Sigma) was used at 40 mg/ml and desmin was detected with mouse monoclonal antibody D33 (DAKO). Endothelial cells were visualized with anti-CD31 (PECAM) antibody 01951D (PharMingen) at 2.5±10 mg/ml (5±7 mm thick frozen sections). Appropriate horseradish peroxidase-,¯uorescein-or Texas Red-conjugated secondary antibodies were used in these experiments. The microvascular density count was carried out by using Northern Eclipse software, version 6. Basic statistical analysis was performed with the GraphPAD InSTAT software, version 1.14 (GraphPAD, Inc.). Tumor stroma was visualized by injecting tumor cells into syngeneic or SCID mice harboring ubiquitously expressed YFP transgene (Hadjantonakis et al., 1998) . Tumors 10±15 mm in diameter were removed, sectioned and immediately analyzed by confocal microscopy (Zeiss). Identi®cation of LacZ-expressing (VEGF-producing) stromal cells was performed after s.c. injection of tumor cells into syngeneic mice harboring a LacZ-tagged VEGF allele (VEGF-LacZ-KI mice). Brie¯y, tumors were ®xed in 0.2% glutaraldehyde and 2% paraformaldehyde, embedded in OCT compound (Tissue Tek), frozen, sectioned and stained as described previously (Miquerol et al., 1999) .
GEArray analysis
Expression pro®ling of 23 angiogenesis-related genes in oncogenetransformed cells (or tumors) versus control MDF528 cells was performed by using the Mouse Cancer/Angiogenesis-2 GEArray kit (SuperArray Biosience Corp., Frederick, MD) following the manufacturer's instructions. Brie¯y, cells were grown to con¯uence (in DMEM 5% FBS) or (transformed cells) inoculated s.c. into SCID mice to generate tumors (100±150 mm 3 ). RNA was extracted using TRIzol method, reverse-transcribed and 32 P-labeled cDNA was hybridized overnight at 68°C to membranes containing immobilized speci®c cDNA probes. The membranes were washed and speci®c bound radioactivity was quanti®ed using PhosphorImager Ô and ImageQuant software 5.0 (Molecular Dynamics). VEGF signal was omitted from analysis of VEGF ±/± cell lines, as it is known to represent an incorrect transcript. The level of gene expression was calculated according to manufacturer's recommendations. Local median was applied for background correction and the volume of each gene spot was averaged (for each two spots) and standardized to the expression of b-actin. The ratio between normalized signal intensity of transformed cells (or tumors) versus parental cells (MDF528) was calculated in each experiment separately, and the data were presented as the average of at least three such independent quanti®cations (6 SD).
